Diamyd Medical AB (publ)

OM:DMYD BTU B Stock Report

Market Cap: SEK 994.6m

Diamyd Medical Valuation

Is DMYD BTU B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DMYD BTU B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 5.10
Fair Value
102.1% overvalued intrinsic discount
1
Number of Analysts

Below Fair Value: DMYD BTU B (SEK10.3) is trading above our estimate of fair value (SEK5.1)

Significantly Below Fair Value: DMYD BTU B is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DMYD BTU B?

Key metric: As DMYD BTU B barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for DMYD BTU B. This is calculated by dividing DMYD BTU B's market cap by their current book value.
What is DMYD BTU B's PB Ratio?
PB Ratio8.9x
BookSEK 111.53m
Market CapSEK 994.63m

Price to Book Ratio vs Peers

How does DMYD BTU B's PB Ratio compare to its peers?

The above table shows the PB ratio for DMYD BTU B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.3x
SYNACT SynAct Pharma
4.2x59.93%SEK 880.2m
XSPRAY Xspray Pharma
1.9x121.09%SEK 1.1b
BINV BioInvent International
2.7x81.76%SEK 2.0b
ACE Ascelia Pharma
8.3x70.29%SEK 449.0m
DMYD BTU B Diamyd Medical
8.9x93.04%SEK 994.6m

Price-To-Book vs Peers: DMYD BTU B is expensive based on its Price-To-Book Ratio (8.9x) compared to the peer average (4.3x).

Price to Book Ratio vs Industry

How does DMYD BTU B's PB Ratio compare vs other companies in the SE Biotechs Industry?

7 CompaniesPrice / BookEstimated GrowthMarket Cap
IMMU Mendus
0.4x28.14%US$27.14m
APTA Aptahem
0.2xn/aUS$1.50m
SPERM Spermosens
0.3xn/aUS$1.12m
PROGEN Prostatype Genomics
0.3xn/aUS$993.78k
DMYD BTU B 8.9xIndustry Avg. 2.4xNo. of Companies13PB0246810+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: DMYD BTU B is expensive based on its Price-To-Book Ratio (8.9x) compared to the Swedish Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is DMYD BTU B's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DMYD BTU B PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio8.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate DMYD BTU B's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

AnalystConsensusTarget
Consensus Narrative from 1 Analyst
SEK 20.02
Fair Value
48.5% undervalued intrinsic discount
1
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 23:32
End of Day Share Price 2025/05/20 00:00
Earnings2025/02/28
Annual Earnings2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Diamyd Medical AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ludvig SvenssonCarnegie Commissioned Research
Ludvig SvenssonPenser Access